News

Endpoints News20h
Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings
Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...
Endpoints News3h
Makary names Vinay Prasad CBER chief; Q1 earn­ings re­port; More on “Most Fa­vored Na­tions"; and more
Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...
Endpoints News23h
Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near
Lonza said on Friday it does not expect any 'material financial impact' from current and potential pharma-specific tariffs.